SCHEMBL5051900

SCHEMBL5051900

O=C(c1ccc2ccccc2c1)N(O)c1ccccc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.58
HPGD P15428 3/20 0.58
ESR1 P03372 1/20 0.57
ESR2 Q92731 1/20 0.57
CES2 O00748 1/20 0.55
CES1 P23141 1/20 0.55
PLAU P00749 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 1/20 0.47
ALDH1A1 P00352 1/20 0.47
EGFR P00533 1/20 0.47
TP53 P04637 1/20 0.47
CYP3A4 P08684 1/20 0.47
MAPT P10636 1/20 0.47
PKM P14618 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
JAK1 P23458 1/20 0.47
MAPK1 P28482 1/20 0.47
KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3453532 0.87 PLAU (0.50) KDM4EHPGDESR1ESR2CES2
SCHEMBL27443700 0.84 ESR1 (0.78) KDM4EHPGDESR1ESR2CES2
SCHEMBL873994 0.82 HPGD (0.72) KDM4EHPGDCES2CES1SMN1; SMN2
SCHEMBL28584481 0.82 MEN1 (0.54) KDM4EHPGDESR1ESR2CES2
SCHEMBL28856499 0.81 ALDH1A1 (0.53) KDM4EHPGDESR1ESR2MEN1
SCHEMBL2470632 0.81 PLAU (0.75) KDM4EESR1ESR2CES2CES1
SCHEMBL11848661 0.81 ESR1 (0.59) KDM4EHPGDESR1ESR2CES2
SCHEMBL133668 0.78 KDM4E (0.67) KDM4EHPGDCES2CES1SMN1; SMN2
SCHEMBL15821561 0.78 CES2 (0.59) KDM4EHPGDESR1ESR2CES2
SCHEMBL3302319 0.78 CES2 (0.59) KDM4EHPGDESR1ESR2CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080096117-A1 Bisazo compound, 2-hydroxy-3-phenylcarbamoyl naphthalene compound and method manufacturing bisazo compound RICOH COMPANY, LTD. 2008-04-24 US claimed
US-7897309-B2 Bisazo compound, 2-hydroxy-3-phenylcarbamoyl naphthalene compound and method manufacturing bisazo compound RICOH COMPANY, LTD. (JP) 2011-03-01 US disclosed
US-7897309-B2 Bisazo compound, 2-hydroxy-3-phenylcarbamoyl naphthalene compound and method manufacturing bisazo compound RICOH COMPANY, LTD. (JP) 2011-03-01 US disclosed
US-20080096117-A1 Bisazo compound, 2-hydroxy-3-phenylcarbamoyl naphthalene compound and method manufacturing bisazo compound RICOH COMPANY, LTD. 2008-04-24 US disclosed
US-20080096117-A1 Bisazo compound, 2-hydroxy-3-phenylcarbamoyl naphthalene compound and method manufacturing bisazo compound RICOH COMPANY, LTD. 2008-04-24 US disclosed
US-4871633-A PHOTOELECTRICAL CHARGE GENERATING COMPOUND MINOLTA CAMERA KABUSHIKI KAISHA (JP) 1989-10-03 US disclosed
US-4618672-A Bisazo compounds useful as charge generating pigments in electrophotography RICOH COMPANY, LTD. (JP) 1986-10-21 US disclosed
US-4314015-A Electrophotographic sensitive materials containing disazo compounds RICOH CO., LTD. (JP) 1982-02-02 US disclosed
US-4299896-A Electrophotographic sensitive materials containing a disazo pigment RICOH CO., LTD. (JP) 1981-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096117-A1 Bisazo compound, 2-hydroxy-3-phenylcarbamoyl naphthalene compound and method manufacturing bisazo compound AHR, PBRM1, AR KDM4E 1277/4885HPGD 3355/4885ESR1 350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.